You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Method to Guarantee Quality of Radiotherapy Planning

    SBC: ADVANCED PROCESS COMBINATORICS, INC.            Topic: N/A

    This project will produce a method for constructing treatment plans with a guarantee on the quality of the solution. The plans produced by current techniques can fall short of the optimum or needlessly fail to satisfy constraints. As a result, the search for an improved solution is open-ended, exhausting hospital resources and manpower, and providing no assurance to patient or physician that a b ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  2. A P. falciparum MSP1 p42/QS-21 malaria vaccine

    SBC: Agenus Inc.            Topic: N/A

    DESCRIPTION: (Adapted from Applicant's Abstract) Malaria is a disease which affects more than 300 million people each year and is fatal for 1.5 million. The overall objective of this STTR Phase I project is to produce a cGMP malaria vaccine consisting of the 42 kDa C-terminal polypeptide of P. falciparum merozoite surface protein-1 (MSP1.42) to be formulated with ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  3. Neuroprotective Drugs for Spinal Cord Injury

    SBC: Biostream Therapeutics, Inc.            Topic: N/A

    DESCRIPTION: (Adapted from the Applicant's Abstract) Traumatic spinal cord injury (SCI) leads to permanent loss of motor function and control of function below the level of the injury. A significant portion of the loss is due to secondary factors rather than the initial trauma. These factors include increased extracellular concentrations of glutamate which ha ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  4. Neuroadaptive effects after chronic CTDP 31446 treatment

    SBC: Biostream Therapeutics, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Cocaine abuse remains a grave concern for the American, and increasingly the world, population. As no current therapeutic agents are available to assist cocaine addicts in achieving and maintaining abstinence it is important that new pharmacotherapies be developed. One important question not usually addressed in the development ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  5. RAPID TEST FOR TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHIES

    SBC: CC Technology            Topic: N/A

    DESCRIPTION (adapted from applicant's abstract): The long-term goal of this project is to develop a rapid, safe, and sensitive test for the abnormal isofomms of prion (PrP/res) proteins associated with the transmissible spongifomm encephalopathies (TSE). The Surface Enhanced Raman Immunoassay (SERIA) assay to be evaluated will facilitate testing of sample ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  6. One Step H. pylori Test--Screening and Individual Assays

    SBC: CC Technology            Topic: N/A

    The aim of this project is to demonstrate feasibility of four different types of H. pylori assays. Assays will be developed for both the H. pylori organism and its antibody. The specific goal will be to develop a test which is rapid and very-low cost for screening of populations and for clinical laboratories. H. pylori is significant as a cancer risk as it can cause two types of malignancies: gast ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  7. A NEW METHOD FOR MONITORING SPECIFIC NEUROTRANSMITTERS

    SBC: CC Technology            Topic: N/A

    DESCRIPTION (provided by applicant): The proposed research will develop two prototype analyzers, one of which will be interfaced with a perfusion probe for neurotransmitters, and their metabolites, Surface Enhanced Raman Assay (SERA) using Surface Enhanced Resonance Raman Scattering (SERRS). The first prototype will be placed in a translational researc ...

    STTR Phase II 2001 Department of Health and Human ServicesNational Institutes of Health
  8. A NEW METHOD FOR MONITORING SPECIFIC NEUROTRANSMITTERS

    SBC: CC Technology            Topic: N/A

    DESCRIPTION (provided by applicant): The proposed research will develop two prototype analyzers, one of which will be interfaced with a perfusion probe for neurotransmitters, and their metabolites, Surface Enhanced Raman Assay (SERA) using Surface Enhanced Resonance Raman Scattering (SERRS). The first prototype will be placed in a translational researc ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  9. Development of a Truly Lattice-Matched III-Nitride Technology for

    SBC: CERMET, INC.            Topic: N/A

    Cermet, in collaboration with researchers at Georgia Institute of Technology, proposes to implement a lattice matched III-Nitride technology using existing substrates. The implementation of a lattice matched substrate promises to produce near dislocationfree III-Nitrides for the first time while the use of an existing substrate technology dramatically lowers development cost and reduces the devel ...

    STTR Phase I 2001 Department of DefenseMissile Defense Agency
  10. Chelate Based Scaffolds (Chelabody) In Tumor Targeting

    SBC: COMCHEM TECHNOLOGIES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The current paradigm in therapeutic nuclear medicine is to optimize receptor binding molecules and then add on a moiety capable of carrying a radioisotope. This "afterthought" modification process results in suboptimum performance for such agents when dealing with molecules smaller than monoclo ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government